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ABSTRACT
Indium Phosphide/Zinc Sulfide (InP/ZnS) quantum dots (QDs) are an emerging option in QD
technologies for uses of fluorescent imaging as well as targeted drug and anti-cancer therapies
based on their customizable properties. In this study we explored effects of InP/ZnS when treated
with HeLa cervical cancer cells. We employed XTT viability assays, reactive oxygen species
(ROS) analysis, and apoptosis analysis to better understand cytotoxicity extents at different
concentrations of InP/ZnS. In addition, we compared the transcriptome profile from the QDtreated HeLa cells with that of untreated HeLa cells to identify changes to the transcriptome in
response to the QD. Intracellular modes of action were illustrated. Our study determined both
IC50 concentration of 69 µg/mL and MIC concentration of 167 µg/mL of InP/ZnS. It was
observed via XTT assay that cell viability decreased significantly at the MIC. In analysis of
median fluorescent intensity (MFI) using ROS assay and flow cytometry, cells positive for
producing both superoxide and peroxynitrite increased in intensity compared to the control.
Using analysis of apoptosis, we found that induced cell death in the QD-treated samples was
shown to be significantly increased when compared to untreated cells. We conclude InP/ZnS QD
to decrease cell viability by inducing stress via ROS levels, apoptosis induction, and alteration of
transcriptome.
KEYWORDS: quantum dot, HeLa, nanoparticle, cancer, apoptosis, genome, InP/ZnS
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INTRODUCTION

Origin and Importance of the HeLa Cell
HeLa cells are widely known for their advancements in medical research as well as their
controversial origin. The cells were named after the woman from which they originated, taking
the first two letters of her first and last name. Henrietta Lacks, a 30 year old African American
woman, arrived at Johns Hopkins hospital in 1951 where she was diagnosed with cervical
carcinoma; despite anti-cancer treatment, Lacks passed away later that year [1]. Meanwhile, Dr.
George Gey was in the tissue research laboratory searching for a continually culturable tissue,
where he had been unsuccessful until receiving biopsy samples from Ms. Lacks [2]. After
realizing the power of her cells Dr. Gey began sending tissues to researchers around the country.
Gey’s name quickly gained recognition, however, the identification and due credit to Henrietta
went unspoken for many years [1]. While doctors were unable to save Lacks, her cells have lived
on to become the first “immortal” human cells to be used across the world for innovative
treatments and understandings of the human cancer cell [3].

Overview of Quantum Dot Usage
Many advancements have been made in the studies of cancer since the discovery of HeLa
cells and specific interest has been placed on the use of quantum dot (QD) nanoparticles. First
described by Ekimov et. al. as semiconductor crystals, QDs have been widely studied for their
optical properties [4]. This observation of QDs is due to their unique ability to absorb photons,
which results in the formation of an electron-hole pair/exciton [5]. When an electron is excited
by the bulk valence band of a semiconductor, an electron-hole pair is formed; it is then confined
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within the nanocrystal until recombined and colored light is emitted [6]. Additionally, changing
the size of QD varies the emitted color. Due to this, QDs are becoming increasingly competitive
compared to older technologies [4]. This fluorescent quality has attracted interest of many for the
purpose of cancer research. The QD may act to visualize intracellular networks, marking cancer
cells for diagnostic purposes, increasing radiation efficiency, targeted drug delivery, and to
detect change of extracellular pH [5, 7, 8]. The applications of QDs is obviously wide spread,
due to the ability to alter the composition, size, and surface charge to customize the QD to each
project.

Customizable Properties of Quantum Dots
One of many ways to customize QDs is by their core composition. Most commonly,
variations of Cadmium (Cd), Silver (Ag), and Indium (In) have been observed. The core material
can be coupled to other elements to yield varying effects on cell survival. For example, T. Zhang
et. al. compared three variations of Cd QDs (Cadmium Telluride (CdTe) of 2.2 nm and 3.5 nm,
and Cadmium Selenide (CdSe) of 2.2 nm) when applied in vitro to mouse fibroblasts. Their
findings showed that the effects of QD treatment vary when changing the core and size.
Treatment with 2.2 nm CdTe induced significantly higher levels of oxidative stress and
percentage of apoptotic cells than the other two treatments [9]. Due to the varying toxicity that
has been observed, scientists are still investigating other semiconductors with safer properties for
clinical use. This hypothesis will be investigated in greater detail throughout this study and
demonstrates that the choice of core composition should be carefully selected in QD treatment
for the safest and most effective results.
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As mentioned, changing the size of QDs changes the color of fluorescence. The relationship
for this phenomenon is inverse: larger quantum dots emit lower frequencies and smaller quantum
dots emit larger frequencies. The resulting color correspond to wavelengths on the color
spectrum, ranging from green (495-570nm) to red (620-750nm). This property is especially
important to evolving imaging technologies and has been a study of focus for many. For
example, Kim et al. tested the imaging of breast cancer cells both in vitro and in vivo. To do so,
Cadmium Selenium/Zinc Sulfide (CdSe/ZnS) QDs and siRNA were coupled to liposomes and
viewed in breast cancer cells using fluorescent confocal imaging; their study successfully
identified cellular uptake of QDs in vitro and shows that QDs localized to tumor tissue in vivo. It
was importantly noted that the highest signal was detected after 8 hours of incubation [10].
It is known that far-red light travels well through human tissue, giving red-emitting QDs the
potential for advancing in vivo imaging. Previously in pre-clinical oncology research, the use of
red fluorescent protein for fluorescent tomography shows this as a non-invasive method to
monitor tumor progression [11]. The same concept could therefore could be applied to red
fluorescent QDs targeted to tumor cells. Improvements in pre-clinical imaging of tumors will be
invaluable to monitoring and treating cancer going forward.
Another use for QD imaging (specifically using blue light, wavelength 450-490nm) is
exemplified by Zheng et. al. in their efforts to quantify gene expression of breast cancer tissues.
The aim of this study was to compare QD-based imaging to the conventional
Immunohistochemistry (IHC) technique; their results indicate that use of secondary antibodies
conjugated to the QD, instead of traditional fluophores, yields better quality data, improved
accuracy, and lower background disturbance than current technologies [12]. The findings of both
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studies shed light on potentially clinical applications of QDs for mapping and characterizing
cancer cells/tissue.
Along with improving imaging technologies, the ability to conjugate QDs to specific ligands
is also noteworthy. This can be accomplished in various ways, including a biotin-streptavidin
link between QD and target cell [13]. A QD-probe can also be targeted to cancer tissue via
conjugation to tumor-specific antibody fragments or peptides; these advancements can detect and
measure biomarkers that will go on to broaden our understanding of tumor microenvironments
[14].
Besides the change in color, different sized QDs have also been seen to have varying levels
of intracellular toxicity. Previously, smaller QDs decrease cell viability significantly more than
larger QDs, potentially due to their ability to cross the cell membrane more easily [15]. Green
CdSe/ZnS QD’s (530-550nm) specifically have been seen to reduce HeLa cell viability greater
than yellow (570-585nm) [16].
Another option in customizing quantum dots is changing the surface composition. The
chosen surface molecule acts as a ligand for the QD and allows for selective interaction via facet
charge. The three commonly studied charges are anion, neutral, or cationic and are respectively
referred to as X-type, L-type, and Z-type [17]. While each charge poses its own unique
advantage, it has been previously tested that carboxylic acid (R-COOH) X-type ligands are most
effective in studying cellular uptake mechanisms. In their study, Zhang & Monteiro-Riviere
compared dendritic cell uptake of CdS/ZnS QD coated in each type of ligand: anionic carboxylic
acid (COOH), neutral polyethylene glycol (PEG), and cationic PEG-amine (NH2). Carboxylic
acid coated QDs were much more easily taken up by the dendritic cells compared to positive and
neutral ligands; it was theorized this is a result of carboxylic acid groups being recognized more
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frequently by cellular organelles and receptors [18]. In a similar study, Lin et. al. observed
aerosol pulmonary inhalation of Indium Phosphide/Zinc Sulfide QDs with each of the three
surface ligands in mice. Indium, a metal in group XIII, is combined with phosphide, a P 3- ion,
and coated with a Zinc Sulfide shell to become InP/ZnS. While all three variations of QD were
successfully inhaled, the neutral coating (OH group) deposited the greatest amount of QD; in
observance of lung tissue damage, only the Z-type coating (NH2 group) showed signs of causing
alveolar septal hyperemia [19]. Collectively, it is important to take surface charge into account
when selecting QDs for different exposure routes and test organisms. In the present study
understanding the mechanism and result of cellular uptake is desired, leading to X-type COOH
surface coated QD to be selected for observation.

Resulting Toxicity from Quantum Dot Treatment
As discussed, QDs have raised alarm for inducing cytotoxicity within contacted cells.
Among these potentially harmful QDs, those composed of cadmium (Cd) cores, such as CdSe,
CdTe, and Cadmium Sulfide (CdS), are the most commonly studied and have become well
known for reducing cell viability. Cadmium is a transition metal, located in group XII of the
periodic table, and is known for being a human carcinogen. The toxicity of this core has been
linked to a result of Cd2+ ions that damage the cells it comes into contact with [20]. Studying the
effects of Cd specifically within HeLa cells, Hens et.al. found CdS/ZnS QD that emit green light
reduced cell viability more extensively than the same QD emitting yellow fluorescence, further
suggesting different sizes of QD can be more harmful than others [16]. Another example of
cellular damage from Cd QD exposure is shown by Roberts et. al. in which they show lung
inflammation and injury after pulmonary exposure in mice; measurable damage peaked 7 days
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after exposure. The authors used fluorescent imaging to hypothesize that the QD is destabilized
by the lung, resulting in removal of the stabilizing ZnS shell and subsequent release of free Cd
that resulted in tissue inflammation/damage [21]. This trend was observed similarly in vivo by
M. Wang et. al., where Cd QD induced tissue damage was also most significant after 7-14 days.
The authors suggest the damage can be reversible in time, as damage was reduced at day 28 posttreatment [22].
Solutions to QD toxicity are currently being tested. Shells of ZnS have been added around
the Cd QD core and have shown to slightly reduce cytotoxicity and highly improve
biocompatibility [23]. It is hypothesized that the shell prevents Cd2+ ions from leaking out of the
core and into the affected cell. Observed by Williams et. al., membrane disruption and stability
vary with the number of shell monolayers, as well as the core structure [24]. Horstmann et. al.
explains that the relationship between the core and shell possibly affects the stability of the QD.
Therefore, the number of layers and core composition should be adjusted for maximum strength
and functionality [25].

InP Alterative to Cd Quantum Dot
As cytotoxicity of QDs with Cd core is a rising concern within the field, alternative cores are
being investigated. Indium Phosphide/Zinc Sulfide (InP/ZnS), prepared in the same manner as
Cd/ZnS QDs, was introduced by scientists as a safer option to Cd QDs [20]. Being an underdeveloped field, there is not enough data to confirm whether InP QD is more/less toxic compared
to Cd. So far, studies have found varying conclusions. For example, Ayupova et al. found, in
macrophage-like cells, InP/ZnS treatment yielded significantly lower cytotoxicity than Cd QD
treatment based on viability and reactive oxygen species (ROS) observations [26]. In lung-
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derived cell lines, InP/ZnS treatment increased apoptosis and ROS generation at high
concentrations [20]. The authors warn that InP still yields cytotoxicity and note that
concentration and surface composition should be carefully considered in future applications.
Understanding the inflammatory response to InP/ZnS treatment is also important to determining
their safety in clinical settings; shown by S. Chen et al. IL-6 (an inflammatory cytokine) was
stimulated upon treatment, resulting in acute inflammation and oxidative stress within
macrophages [27]. Overall, detailed properties should be adjusted when making InP/ZnS QDs so
that the most effective and safe combination can be used going forward.
The cytotoxic effects of QD treatment have scientists concerned for their safety in
mammalian cells. However, what if it were possible to harness the toxicity of QD for good? With
a better understanding of the mechanisms of QDs, they could be useful tools in anti-cancer
therapies. Specifically, they have been speculated for use of targeted drug delivery and
photodynamic therapies [28]. The trick will be to design a QD able to penetrate and destroy
cancerous cells, while leaving regular tissue unharmed. As current literature has yet to conclude
whether this is possible, the present study aims to make progress in understanding if InP QD
could be the right material for the job. With expanded research and knowledge about this
alternative QD, it can be determined if InP is a safe, yet effective, treatment to use against
cancerous mammalian cells.

Problem Statement and Hypothesis
In this study, we aimed to observe and expand knowledge on the effects of InP/ZnS QD
when introduced to HeLa cells. To investigate the claim that InP is a less toxic alternative to Cd
QD, we hypothesized InP/ZnS to not decrease HeLa cell viability. To test this, we used XTT cell
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viability, reactive oxygen species, and apoptosis assays. We also compared the transcriptome of
treated HeLa cells to the human genome. Our findings led us to map physiological pathways that
explain how QDs can interact with the cell. Prior research of InP QDs is limited, however, the
present study’s findings provide promising insight to the use of QDs as an effective anti-cancer
therapy.
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MATERIALS AND METHODS

InP/ZnS Quantum Dots
InP/ZnS QDs conjugated with carboxylic acid ligands were obtained from NN-Labs
(Fayetteville, AR, USA) and suspended in water (1 mg/mL). The QDs are capped with ZnS shell
surrounding the InP core for stability and to improve biocompatibility. Green InP/ZnS QDs emit
at 530 nm +/- 15 nm and are 3.7 +/- 0.5 nm in diameter.
A chemical and physical properties analysis of the commercially purchased QDs was
conducted using scanning transmission electron microscopy (STEM), energy dispersive x-ray
spectroscopy (EDAX), ultraviolet-visible (UV–VIS) spectroscopy, and dynamic light scattering
(DLS). The stock (INPW530) QD material was diluted to a concentration of 100 μg/mL and was
used for each proceeding study.
A JEOL 7900F scanning electron microscope (SEM) with a scanning transmission electron
microcopy (STEM) detector was used to image the QDs for qualitative dimensional analysis.
The diluted QD dispersion was drop cast onto holy carbon film TEM grids and allowed to air dry
in a desiccator box prior to imaging. Elemental composition of the InP/ZnS QDs was measured
using a Bruker Quantax energy dispersive x-ray spectrometer (EDAX) attached to the SEM. A
thick film of the InP/ZnS QDs was deposited using a drop cast method onto a silicon substrate
prior to analysis.
Dynamic light scattering (DLS) technique was used to characterize the hydrodynamic size of
the InP/ZnS QDs which were diluted in water and cell media. The diluted samples were tested
with a Malvern Panalytical Zetasizer® Ultra with laser wavelength of 632 nm and scattering
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angle of 173◦. The UV-Vis absorption spectrum was recorded with a Shi- madzu UV3600 UVVis-NIR Spectrometer with scan range of 200 nm to 800 nm and a step size of 0.5 nm.

Cell Culture
We chose two cell types for the present study: HeLa-S3 cells (authenticated by Genetica
Labs of Burlington, NC) and mouse fibroblast. The protocols for both cell lines were the same.
First, cells from a -80 C freezer thawed to 37 C. To collect a pellet, the thawed cells are
immersed in Dulbecco’s Modified Eagle Medium (DMEM) prepared with 10%
penicillin/streptomycin antibiotics and 10% Fetal Bovine Serum (FBS). Removal of the
supernatant after centrifugation (440g for 10 min) reveals a cell pellet that is then resuspended in
13 mL of prepared DMEM+PS+FBS. Plated cells then grew until confluent in an incubator
maintaining 37 C with an atmosphere of 5% CO2/95% air; changing the media every few days
allowed for maintenance of cell growth.

XTT Viability Assay
Both HeLa-S3 and mouse fibroblast cells separately underwent XTT viability assay to
compare effects of InP/ZnS QDs on cancerous and non-cancerous mammalian cells. Biotium
manufacturer protocols led the experimental design development. After seeding (7,500
cells/well) into a flat-bottom, 96 well plate, the cells incubated at 37C for 24 hours. On the
second day, fresh DMEM replaced the previous media (100 µL/well). Designated treatment
wells were given 20 µL of InP/ZnS and serially diluted by a factor of five to give a concentration
range of 0.13 µg/mL to 167 µg/mL. Additional wells served as a positive control and contained
Dimethylsulfoxide (DMSO) at three different concentrations: 5, 10, and 15 %. The plates then
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incubated for another 24 hours. The following day, an XTT solution was prepared in 1:200 ratio
of XTT solution and XTT Activation Reagent (PMS) respectively. The solution applied to each
well of the plate (25 µL/well) and remained for 7 hours at 37 C. Formazan dye formed in the
wells to allow for quantification of viable cells using BioTek ELx880 Absorbance Microplate
Reader (absorbance measured at wavelength 450 nm and 630nm). Subtracting the absorbance
value at 450nm (A450) by the absorbance at 630nm (A630) accurately measures the amount of
dye, and level of viable cells, after 7 hours. A total of two trials of this experiment were
completed; in each trial, each sample was done in triplicate experimental replicates.

Calculation of IC50 Value
The AAT Bioquest website (https://www.aatbio.com/tools/ic50-calculator) calculated the
concentration at which 50% of cell growth was inhibited (IC50). Data from XXT cell viability
assay uploaded to the equation and calculated IC50 to be 69 µg/mL. The equation used can be
seen in Equation 1. The calculated IC50 value further applied to all consecutive experiments as
the main treatment concentration.

Reactive Oxygen Species Assay
Reactive oxygen species (ROS) assay took place over a three-day period. To begin, fresh
HeLa cells seeded into two separate 24-well plates (50,000 cells/well) and incubated for 24
hours. Following this, InP/ZnS QDs then applied equally to both plates in two different
concentrations: 69 µg/mL and 167 µg/mL. The plates incubated for another 24 hours. On the
third day, the cells needed to be detached from the well to be available for harvest. After removal
of DMEM, 500 µL of 1xPhosphate-buffered saline (PBS) washed each well two times. The
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1xPBS was removed so that 250 µL of trypsin + ethylenediaminetetraaceticacid (EDTA) could
submerge each well for 15 minutes to detach cells. DMEM (250 µL/well) adds to the trypsin in
each plate well after incubation and each detached sample then transferred to 2 mL
microcentrifuge tubes. These centrifuge for 10 minutes at a speed of 400 x g. During
centrifugation, 0.5 mg of indicator and 1 mL DMSO mixed to create two ROS indicator
solutions (Dihydroethidium (DHE) and Dihydrorhodamine 123(DHR)). The samples obtained
from one plate receive DHE solution and the other DHR. Removal of the supernatant in each
centrifuged tube left a pellet to be resuspended in 10 µL of the corresponding indicator and 990
µL of 1xPBS. Foil protected the samples from light exposure and covered them during a 30minute incubation at 37 C before being analyzed by Life Technologies Attune NxT Flow
Cytometer. Samples dyed with DHE measure at 518/606 nm and those with DHR at 507/536nm.

Apoptosis Assay
Before beginning the apoptosis assay, 10X Annexin V Binding buffer was prepared by
mixing concentrations of 0.1M HEPES, 1.5M sodium chloride (NaCl), 25mM calcium chloride
(CaCl2), and molecular grade sterile water. For experimental use, 18 mL of 1xPBS diluted 2 mL
of the 10X Annexin V Binding buffer to be a 1x solution. To initiate the experiment, HeLa cells
seeded at 50,000 cells/well into a 24 well plate. After incubating for 24 hours, treatment applied
at two different concentrations of InP/ZnS QDs: 69 µg/mL and 167 µg/mL. On the third day,
1xPBS washed each well two times and non-EDTA trypsin (250 µL/well) detached the cells
from the bottom of the well. Following incubating for 20 minutes, 250 µL of DMEM adds to mix
with the trypsin. The samples, then transferred to microcentrifuge tubes, centrifuged for 10
minutes at 2000 x g and the supernatant was removed. The remaining pellets of untreated and
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negative control samples resuspended in 500 µL 1xPBS. Positive controls and treated samples
resuspended in 100 µL 1x Annexin V Binding buffer, 5 µL Annexin V-APC (measuring early
apoptosis), and 5 µL propidium iodide (PI) (measuring late apoptosis). Once incubating in the
dark for 30 minutes, another 400 µL of 1x binding buffer was added to the samples. Life
Technologies Attune Nxt Flow cytometer then measured each sample based on the excitation
properties of the dyes. Annexin V-APC emits at 650 nm with a red laser, and PI emits at 617 nm
with a blue laser.

Total RNA Extraction and cDNA Conversion
HeLa cells treated with 100 µg/mL InP/ZnS underwent a total RNA extraction in order to
analyze changes to the cell transcriptome. To begin, 750,000 cells seeded into each well of a 6
well plate and incubated for 24 hours. Using Invitrogen TRIzol protocols, total RNA was
extracted and resuspended in 30 µL of nuclease-free water. Qubit 3.0 Fluorometer at 280 nm OD
measured the concentration of RNA in each sample. TruSeq Stranded mRNA LT Sample
Preparation Kit (Illumina, San Diego, CA) isolated mRNA. One ng of mRNA isolate synthesized
6 cDNA samples, 3 non-treated and 3 InP/ZnS treated, with Verso Reverse Transcriptase kit
(using Thermo Scientific protocol). A different adaptor ligated each sample and amplified it 15
times in T100TM Thermal Cycler (BIO-RAD). The resulting cDNA served for subsequent
transcriptome analysis.

RNAseq Transcriptome Analysis
To determine significantly altered genes, the University of Kansas Medical Genome Centre
sequenced cDNA samples of treated and non-treated cells. Illumina Hiseq 2500 sequencing
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system processed cDNA samples with 100 nucleotide sequences of each end. The data then
uploaded to the Basepair Tech website (www.basepairtech.com). From there, the website
conducted pipeline RNA-seq and total expression count on the sequences. Results were aligned
with the human reference genome (hg19) via differential expression (DESeq2) to produce a list
of effected genes. The list of genes transferred to GOrilla, where Microsoft Excel grouped Gene
Ontology (GO) terms by significance and function.

Statistical Analysis
Each analysis was repeated multiple times and the most consistent trial was reported. Within
each experiment, every sample had 3 experimental replicates that were then averaged during
analysis. GraphPad Prism 8.0 statistically analyzed data of all experiments. One-Way ANOVA
analysis and Dunnett’s multiple comparisons visualized any variance among control and
treatment groups. Statistically significant data is represented on graphs as * p < 0.05, ** p <
0.01, *** p < 0.001, **** p < 0.0001.
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RESULTS

Chemophysical Properties of Green InP/ZnS
A JEOL 7900F scanning electron microscope (SEM) with a scanning transmission electron
microcopy (STEM) detector was used to image the individual QDs. The sample INPW530
(InP/ZnS – 530nm) was diluted to a concentration of 0.1 mg/mL and subsequently drop cast onto
holy carbon film TEM grids and allowed to air dry in a desiccator box. Figure 1 shows the
STEM images which approximates the InP/ZnS QD particle sizes in agreement with that of the
data sheet values (3.7 – 5.2 nm).
Elemental composition of the InP/ZnS QDs was measured using a Bruker Quantax energy
dispersive x-ray spectrometer (EDAX). A thick film of each of the InP/ZnS QDs (530nm) was
deposited onto silicon substrates. The spectra of QD sample is provided in Figure 2, which
verifies the InP/ZnS composition.
Dynamic light scattering (DLS) technique was used to characterize the hydrodynamic size of
InP/ZnS quantum dots dispersion in aqueous solution. QDs samples at 0.1mg/mL were tested by
Malvern Panalytical Zetasizer® Ultra with laser wavelength of 632nm and scattering angle of
173°. DLS results (Figure 3) showed a monodisperse peak with hydrodynamic diameter of
72.3nm InP/ZnS. The results indicate that there might be formation of ligands shells (carboxylic
acid ligands) and also possible aggregations when the QDs were dispersed in aqueous solution.
UV-Vis absorption spectrum was recorded by a Shimadzu UV3600 UV-Vis-NIR
Spectrometer with scan range of 200 to 800nm and step size of 0.5nm. A sample was diluted to
0.1mg/ml by DI water. InP/ZnS showed no absorption at or above wavelengths of 650nm (Figure
4a). The first absorption peak for InP/ZnS were around 470nm (Figure 4b).
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The thick film of InP/ZnS QDs that were deposited onto silicon substrates were excited using
a UV source at 365nm. Figure 5 shows the excitation at 530nm (Green).

Effect on Cell Viability When Treated with InP/ZnS QD
To examine the toxicity of InP/ZnS QD when treated to HeLa cells, an XTT assay was
performed. Cells were treated with concentrations ranging from 0.13 µg/mL to 167 µg/mL,
serially diluted by a factor of 6x for 24 hours (Figure 6A). Then, XTT assay dye was added.
When cells are alive, mitochondrial enzymes reduce the XTT dye to form an orange color. The
generated color is measured by absorbance and is equivalent to the number of viable cells
(higher absorbance equaling higher cell viability). After 7 hours of incubation with XTT dye,
HeLa cell viability was reduced to approximately 68% when treated with 167 µg/mL InP/ZnS
compared to the non-treated control. At this concentration, samples averaged an absorbance level
of 0.23, which was deemed statistically significant by One-way ANOVA test (Figure 6A). All
other concentrations, including the control, averaged absorption levels between 0.31-0.33. Based
on these results, 167 µg/mL was used as the minimum inhibition concentration for further
experiments. DMSO (concentration ranging from 5%-20%) was used as a positive control and
showed lower absorbance levels compared to the non-treated control (NTC).
Mice fibroblast cells were tested in the same manner to observe effect of InP/ZnS treatment
in non-cancerous tissue. Interestingly, there was an increase in cell viability compared to the
NTC in all concentration levels (Figure 6B). Treatment concentrations ranged from 0.13 µg/mL
to 167 µg/mL; at the highest concentration, absorbance increased to 0.36 (compared to the
control of 0.19). This finding is highly valuable in the potential of InP/ZnS QDs in cancer
treatment. The ability of the chemical to decrease viable cancer cells while leaving non-
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cancerous tissue unharmed is very desirable. Expanding the studies on InP/ZnS QD treated
fibroblast tissue will improve the viablity of the result and plausibility of these QDs as anticancer therapy.

Increased Production of Superoxide and Peroxynitrite Radicals in InP/ZnS Presence
The production of Reactive Oxygen Species in the form of free radicals is a known
reaction of cellular metabolism that, when increased, plays a large role in disturbing the
survival of the cell in stressful environments. ROS are produced in several organelles
including the mitochondria. While normal levels of mitochondrial ROS are managed by
antioxidant mechanisms, oxidative stress caused by elevated ROS results in mitochondrial
dysfunction and activation of cell death pathways [29, 30]. We tested for ROS production of
two molecules in cells treated with 69 µg/mL and 167 µg/mL InP/ZnS. Samples were dyed
with dihydroethidium (DHE) to measure cells producing superoxide radicals and with
dihydrorhodamine (DHR) to measure those producing peroxynitrite. If cells exhibit
fluorescence at a peak excitation wavelength of 518nm due to DHE treatment (or 530nm,
due to DHR treatment), then they would be positive for producing superoxide radicals (or
peroxynitirite). As each sample was repeated in triplicate, the average for each concentration
level was compared via bar graph (Figure 7A&B). Fluorescent peaks of each sample were
observed with flow cytometry and gates were used to measure percentage of cells producing
ROS (Figure 7C-H). When measuring the entirety of present cells, those treated with
InP/ZnS exhibited fewer fluorescent positive cells than in the dyed, non-treated control –
revealing a significant decrease in superoxide radical production compared to the dyed, NTC
(Dyed control averaging 79.18% ROS production). Both concentrations of InP/ZnS
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treatment yielded similar percentages of change; 69 µg/mL InP/ZnS averaged 56.34% ROS
positive cells and 167 µg/mL InP/ZnS averaged 51.89% (Figure 7A). Based on the use of
the DHR dye, InP/ZnS treated cells exhibited an increased production of peroxynitrite
(averaging 57.85% ROS positive cells) as compared to the NTC (Figure 7B). Again, the
increased amount of peroxynitirtie positive cells were similar at both concentrations of
treatment. Samples treated with 69 µg/mL InP/ZnS averaged 79.28% ROS production, while
those treated with 167 µg/mL InP/ZnS averaged 78.13%.
Continuing the analysis, median fluorescent intensity (MFI) was also measured to
calculate an accurate level of ROS production only in living, viable cells. MFI also shows
intensity/degree of ROS production. MFI measurements revealed an increase in both
superoxide and peroxynitrite positive cells compared to the NTC as well as a greater
intensity of ROS (Table 1). As the original measurements (Figure 7) included unviable cells,
it is likely the decreased levels of superoxide is due to a significant amount of cells already
being unviable and incapable of producing ROS. By only observing viable cells with MFI,
the measure of ROS producing cells is more accurate to analyzing the change compared to
NTC. Collectively, I hypothesize the QD treatment to significantly increase production of
both superoxide and peroxynitrite ROS molecules. The increase could also be causing
oxidative damage and induction of cell death, which would henceforth explain the large
amount of unviable cells disrupting the appearance of the original measurements. As
superoxide radicals are formed in the mitochondria, they can collide with nitric oxide to
form peroxynitrite; this causes cellular dysfunction and cell death [31]. This pathway could
help further explain the observed increase in peroxynitrite production, as more superoxide (a
reactant) became available to make-up the product.
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Increased Late Apoptosis with InP/ZnS Treatment
Increased levels of ROS induce stress upon affected cells by causing damage to multiple
intracellular components, which often leads to induction of apoptosis [32]. Understanding
how apoptotic-like programmed cell death occurs is important to elucidating tumor
suppression mechanisms and advancements in anti-cancer drugs [33]. We tested for an
induction of apoptosis in cells treated with 69 µg/mL and 167 µg/mL of InP/ZnS QDs
(Figure 8A-E). Our results were divided into early and late apoptosis and observed with
gated quadrants using flow cytometry (Figure 8C-E). Early apoptosis involves the activation
of multiple signal cascades and can be measured by the presence of phosphatidylserine (PS)
in the plasma membrane (detected with annexin V); late apoptosis represents the
fragmentation of DNA and the loss of cell membrane integrity [34]. In both concentrations
of treatment groups, the amount of cells undergoing apoptosis was decreased in the early
phase and increased in the late phase. The dyed control for early stage (Figure 8A&C)
averaged 27.7% of cells undergoing apoptosis, while that for late apoptosis (Figure 8B&D)
averaged 0.69%. There was not a significant difference in the two concentrations of
treatment, indicating the IC50 (69 µg/mL InP/ZnS) is a sufficient dose to change levels of
apoptosis. At 69 µg/mL InP/ZnS, early apoptosis averaged 15.24%, a 45% decrease from the
control group. At 167 µg/mL InP/ZnS, samples averaged 19.48% early apoptosis- a 29.7%
difference decrease compared to NTC. As for late apoptosis, 69 µg/mL InP/ZnS averaged
31.28%, nearly 4417% increase from the control group. 167 µg/mL InP/ZnS averaged
23.67%- a 3317%.
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Altered Genome with InP/ZnS Treatment
RNA-seq results aligned with the human reference genome showed 16.4k genes
differentially expressed. The data were filtered for p-value < 0.05, which resulted in 620
downregulated genes and 1129 upregulated genes. The 1129 upregulated genes were sorted by
function and yielded strong activation of developmental processes (such as cell differentiation,
tissue and nervous system development, and morphogenesis) and signal transduction (including
stimulus responses, G protein-coupled receptor signaling, and inflammatory responses) (Figure
9A). Specific genes involved with developmental processes include LGALS9, ZSWIM4, and
IFITM1; those involved with signal transduction are RFNG, MEIS3, and SYN1. The same
process was performed with the 620 downregulated genes. This yielded major disruption (over
300 altered genes) of metabolic processes and biosynthetic process regulations (Figure 9B).
Those involved with metabolic processes included NCBP2, DPM1, and BCAS2; biosynthetic
process genes included PSMC6, PSMD12, and PSMD14. A second filter was then applied to
select genes with a log2 fold change greater than 1. This resulted in 69 downregulated and 408
upregulated with p < 0.05 and log2 fold change > 1 (Figure 9C-D). The functions of the highly
downregulated genes were investigated to show significant disruption to cell growth regulation,
protein quality controls, and mitochondrial function. Notable genes in this category are PDK4,
ID2, SRRM4, and MMP13. Highly upregulated genes commonly coded for transmembrane
proteins to alter proliferation, apoptosis, cellular transport, and organization. Significant genes
for upregulation include TIMP1, ZSWIM4, and LGALS9.
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DISCUSSION

QDs have potential to advance medical techniques such as molecular imaging and anti-cancer
treatment. InP/ZnS QDs have been proposed as a safer alternative to Cd based QDs but have not
been previously investigated enough to understand how they alter cellular homeostasis, function,
and the transcriptome. This study aims to fill the gap in this knowledge. Through a series of
experiments, we suggest the impact of InP/ZnS QDs interacting with HeLa cells and the results
they have. We found increased levels of oxidative stress and apoptosis, supporting previously
stated hypotheses positing that toxicity is associated with QD treatment. Investigation of the
transcriptome via RNA-seq offers evidence of transcriptome alteration and are explained with
diagrams mapping genetic alteration throughout the cell. Our findings are significant for
understanding more about the effects of InP/ZnS QD exposure, but further investigation is
required to understand if they are a viable technology for medical treatment.

Changes to HeLa Cell Viability, ROS, and Apoptosis Levels with InP/ZnS Treatment
When observing cell viability after 24 hours of InP/ZnS treatment, 167 μg/mL InP/ZnS
significantly decreased cell survival by 32%. Among the current data, the consensus on InP/ZnS
effect on cell viability seems to vary by cell type and length of treatment. For example, Chen T
et. al. observed varying decrease in viability after 24 and 48 hours of treatment to human lung
cancer cell (HCC-15) and alveolar type II epithelial cell (RLE-6TN) (treatment concentrations
ranging 80-160 μg/mL InP/ZnS). Treatment of REL-6TN cells at 160 μg/mL resulted in 80%
viability after 24 hours, which reduced to 40% viability after 48 hours [20]. In a similar study,
treatment for 24 hours at 80 μg/mL and below did not significantly decrease cell viability in bone

21

marrow-derived macrophages of mice [27]. Collectively, these findings suggest that HeLa cells
are susceptible to InP/ZnS related damage and are shown in the present study as reduced in
viability by 32% compared to NTC. The degree of susceptibility seems to vary across cell lines,
and impact greatens with treatment dosage. Further investigation with varying treatment
concentrations and length of exposure could aid in better understanding this comparison.
The decrease in HeLa viability may be supported by RNAseq results as well. Presently,
ATF3 is slightly upregulated by InP/ZnS QD treatment (0.23 fold change). Fan et. al. observed
the ATF3 response to DNA damage in HeLa cells, finding the overexpression to potentially slow
the cell cycle progression [35]. The use of InP/ZnS QD treatment to prevent cancer cell growth
via genetic alteration could be an important of HeLa studies going forward.
The influences of QDs on ROS production, specifically InP/ZnS QDs, has been previously
reported [36–39]. ROS consist of many metabolites that induce stress within the cell including
superoxide, hydrogen peroxide (H2O2) and peroxynitrite. Each of the metabolites mentioned are
measured with a different fluorescent probe: DHE, DCFH-DA, and DHR, respectively.
Additionally, superoxide can merge with nitric oxide to form peroxynitrite, or superoxide
dismutase to make H2O2. Focusing on DHE and DHR, we observed cellular production of
superoxide radicals and peroxynitrite levels increased when analyzing only viable cells. Current
literature is in agreeance with our finding as QDs have been seen to induce ROS production
across many different cell types. For example, Ayupova et. al. also reports increased production
of superoxide radials in RAW 264.7 murine “macrophage-like” cells after InP/ZnS QD treatment
(1 mg/mL); they also observed a decrease in the anti-oxidant GSH which would allow for
cellular oxidative stress to progress [26]. T. Chen et. al. reported significant increases in ROS (in
form of H2O2) in two different lung-derived cell lines which they pose to explain the observed
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cytotoxicity with InP/ZnS QD treatment [20]. Collectively, QDs seem to be disrupting
mitochondrial function by surging an increase in ROS production; this is likely causing oxidative
stress and induction of cell death.
Increased oxidative stress by ROS has been linked to inducing apoptosis as well. Presently,
we observed a significant increase of late apoptosis. Levels of early apoptotic cells were
decreased, likely because most of the active cells had already shifted towards the late stage of
cell death. Cells positive for early apoptosis were observed in the dyed control as well (Figure
8A); it is possible this is a result of drying during culturing or damage during plate detachment
via trypsin.
T. Chen et. al. also observed increased levels of ROS and apoptosis in lung derived cell
lines. This is consistent with an observed increase of late apoptosis in our study, however T.
Chen el. al. reported significant increase of apoptosis at a much lower concentration of InP/ZnS
QDs (20 μg/mL compared to 69 μg/mL and 167 μg/mL) [20]. At 28 μg/mL InP/ZnS, we did not
find cell viability to be significantly changed (Figure 6); variation in InP/ZnS toxicity is
documented between cell types and presents an area of study to be expanded in the future.

Upregulated Gene Processes Increase ROS Production and Induce Apoptosis
After observing increases of ROS and apoptotic induction, we turned to RNAseq data for
upregulated genetic sequences that could support these results. QDs are known to cause ROS
increase by activation of the caspase-1 by assembly of the NLRP3 inflammasome [40].
Presently, CASP1 is upregulated by 0.63 fold change and could help explain the increased ROS
seen with InP/ZnS treatment. Also in HeLa cells, C. trachomatis has been shown to increase

23

ROS and induce CASP1 activation [41]. Collectively with previous data, we hypothesize the
upregulation of CASP1 to support the increased ROS seen in Fig 7.
Supporting our findings of increased late apoptosis (Figure 8), another gene that was
upregulated, LGALS9, has been shown to play a role in apoptosis (Figure 10A). This gene is
responsible for suppressing T-cell proliferation, inducing T-cell apoptosis, and associated with
angiogenesis and cytokine signaling; it has also been studied specifically for anti-cancer activity
[42]. Immune function was observed by Holderried et. al. by investigation of T cell-mediated
tumor evasion. Galactin-9, a ligand made by LGALS9, was upregulated in colorectal tumors and
hypothesized to be a therapeutic target for immune-mediated anti-cancer therapies by inducing
apoptosis [43].
Increased ZC3H12A expression also point to apoptosis. ZC3H12A, a transcription factor, is
proposed to induce apoptotic gene expression and regulate inflammation/stress responses.
Studied in colorectal cancer patients, T. Chen et al. found lower expression levels of ZC3H12A
are seen in more aggressive tumor cells; thus, increasing ZC3H12A expression might be effective
in making cancerous tissue less aggressive [44]. Going forward, targeted therapies could explore
use of this gene for inducing tumor cell death.
We also report up regulation of ZSWIM4, potentially involved in chromatic organization.
We suspect disruption of this gene could lead to disruption of ZC3H12A as well (Figure 10A).
Our results suggest InP/ZnS QDs induces stress on the cell, which increases ZSWIM4 and
ZC3H12A expression and induces apoptosis.
Along with ZC3H12A, LIF and LGALS9 upregulation has been associated with collateral
damage via the immune system. Leukemia inhibitory factor (LIF) is a member of interleukin 6
pro-inflammatory cytokine family and is responsible for inhibiting cell growth and
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differentiation. In their study with elephant cells, Vazquez et. al. report upregulation of LIF
results in DNA damage and leads to apoptosis; the authors propose this to be linked to evolution
of cancer resistance in organisms with long life spans [45]. Immune function of LGALS9 was
observed by Holderried et. al. by investigation of T cell-mediated tumor evasion. Galactin-9, a
ligand made by LGALS9, was upregulated in colorectal tumors and hypothesized to be a
therapeutic target for immune-mediated anti-cancer therapies [43]. Collectively, we suggest
cellular stress could activate the immune system in the presence of InP/ZnS QDs and induce
apoptosis in tumor cells (Figure 10A).
In analyzing up regulated genes from InP/ZnS QDs treatment, genes controlling metastatic
inhibition and increased cell aggregation were overexpressed. Specifically ITGA1, an integrin
protein involved in cell adhesion and surface signaling, has been linked to both apoptosis and
cell aggregation. Saftencu et al. observed papillary thyroid cancer RNA, finding ITGA10, and
other biological adhesion genes, as having prognostic impact by linking increased gene
expression to patient survival [46]. Additionally, TIMP1 is an inhibitor of matrix
metalloproteinase (MMP) and involved in apoptotic pathways of synovial fibroblasts. Prior
studies of Dumortier et al. have shown MMP13 role in breast tumorigenesis. In their findings, the
inhibition of MMP was linked to regulating cell migration and apoptosis [47]. Thus along with
increased induction of apoptosis, we suggest the genetic control of metastasis as a future study
point in the potential of InP/ZnS as anti-cancer therapy.

Downregulated Processes Also Prevent Tumor Growth Via Oxidative Stress
Genetic inhibitions also support our findings of oxidative stress and elevated apoptosis. A
member of the pyruvate dehydrogenase kinase (PDK) family, PDKs function to regulate
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carbohydrate metabolism in mammals by catalyzing oxidative decarboxylation of pyruvate [48].
The presence of PDK4 expression has been said to improve mediation of mitochondrial ROS;
PDK4 deficiency is also suggested to cause mitochondrial-mediated apoptosis as a result of ROS
oxidative stress [49]. RNAseq revealed deceased PDK4 expression (-1.3 fold change) (Figure
10B). We hypothesize this down regulation to support our findings of ROS generation and
subsequent apoptotic induction in HeLa cells treated with InP/ZnS QDs.
Expression of HIGD1A is shown to interact with the mitochondrial electron transport chain
to control ROS production [50]. Currently, we see a decrease in HIGD1A expression (-0.85 fold
change). Its reduction has previously been linked to breast cancer tumor recurrence [51]. It is
noteworthy that the down regulation seen in our RNAseq is likely because we are also observing
a cancer cell. However, it would be interesting to observe this gene more closely in HeLa cells;
possibly targeting the expression in tumor cells could act to control the ROS production
commonly induced by QD treatment. We suggest HIGD1A as a focus for gene-focused cancer
therapies in the future.
Earlier, the up regulation of LGALS9 and ZC3H12A was linked to apoptosis. Similarly,
down regulation of ID2 could provide another mechanism of inhibiting tumor cell proliferation.
ID2 (Figure 10B) has been investigated as an important activator in tumor progression in glioma
and breast tissues [52–54]. We therefore suggest gene targeting as topic of further investigation
for genetic prevention of tumor growth.
Alternative splicing in mRNA creates recombinant and diverse proteomes within a cell and
increases tumor aggressiveness; in previous studies, a common regulator and potential
therapeutic target of this process is SRRM4 [55, 56]. Presently, SRRM4 levels were inhibited by
InP/ZnS QD treatment, possibly showing an ability to alter the SRRM4 communication pathway

26

(Figure 10B). Signaling mechanisms of SRRM4 have been proposed to show an ability to drive
tumor progression, aiding in future development of resistance therapies [57]. We suggest
SRRM4 as another future interest for genetic anti-cancer therapies involving InP/ZnS QD
treatment.
UMODL1 was also down regulated (Figure 10B). This gene is associated with immune and
female reproductive systems and peptidase inhibition, however data explaining its role in cancer
is sparse. Available studies have linked UMODL1 to lung cancer metastasis [58] and ovarian
degradation when upregulated [59]. Originally, we had suspected a decrease in UMODL1
expression to show tissue degradation by excess peptide breakdown. However, this is
contradicting to the findings of W. Wang in which they link ovarian degradation to an increase
of UMODL1 expression [59]. While ovarian and cervical tissues are closely related in the body,
it is important to note that gene response can vary among organ tissues. Linkage to excessive
tissue breakdown pose a negative side effect to InP/ZnS QD treatment in HeLa cells, however an
expansion in testing is necessary to further understand UMODL1’s influence in cervical cancer.
We mentioned above that TIMP1 expression inhibits that of MMPs. We support this with our
RNAseq results yielding increased TIMP1 and decreased MMP13 expressions (Figure 10B).
MMP13 is an MMP transcription factor in the collagenase family. We suspect upregulation of
TIMP1 to have a role in this. MMP13 has been found to be overexpressed in breast cancer tissues
and contributes to the breakdown of ECM collagen to promote metastasis [47, 60]. Stemming
from this, we suggest future investigation on the inhibition of MMPs to evaluate it as a potential
gene target for preventing tumor metastasis via inhibition of ECM degradation.
Our findings support InP/ZnS treatment to have potential in controlling tumor growth by
suppressing proliferation and metastasis. The observed decrease in cell viability contrasts from
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the original hypothesis, as InP was expected to safer for cellular treatment. Because viability is
inhibited, we suggest InP/ZnS QDs to have potential for anti-cancer treatment in mammals.
Before this will be possible, further assessment and understanding is required. We acknowledge
limitations within this study and suggest subsequent experiments with HeLa cells and InP/ZnS
QDs before recommending them to be a safe, reliable option for medical applications and
beyond. While the current study shows a broad range of treatment concentrations, it lacks small
intervals between each. The large gaps in treatment concentrations limit data that would pinpoint
the concentration of InP/ZnS that significantly decreases cell viability. Future studies may focus
on smaller ranges of treatment to understand this point further. The comparison of these results
to Cd QD treated HeLa cells will also be beneficial to determining if InP is less toxic when
compared to CD. With diversified studies, better understanding of QD inflicted toxicity will
progress the potential contribution to clinical treatment and technology.
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CONCLUSION AND FUTURE STUDIES

The toxicity of QDs has raised concerns against their uses in medical and scientific
technology. Being proposed as a safer alternative to Cd based QDs, InP QD were studied for
their effects on viability, reactive oxygen species, apoptosis, and the transcriptome of HeLa cells.
Contrary to the original hypothesis, InP/ZnS exposed cell viability was depleted, while ROS and
apoptosis levels were elevated (69 and 167 μg/mL). The transcriptome had many alterations in
presence of the InP/ZnS QD that can be linked to preventing proliferation and metastasis, as well
as inducing apoptosis and cytokine release. Thus, our data does not support the claim InP/ZnS
QDs is necessarily safer than Cd QDs. However, the cytotoxic result to a mammalian cancer cell
suggests their potential to be an effective treatment against tumor progression. Our analysis of
the transcriptome suggests future studies to extend possibility of InP/ZnS QDs for controlling
tumor proliferation and metastasis. The lack of effect to fibroblast cells is notable for clinical
applications. Going forward, studies should further investigate treatment to non-cancerous
tissues to assess use in cancer therapy. A direct comparison of Cd and InP/ZnS treated cells will
also be valuable in identifying which QD exerts greater toxicity. Additionally, comparison of
different sized InP/ZnS QDs can also be useful in determining the most effective for treatment
options.
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Equation 1. Inhibition Concentration 50% (IC50) Equation form used on AAT
Bioquest website (https://www.aatbio.com/tools/ic50-calculator) to calculate IC50
value. This value was used in following experiments as the tested treatment
concentration.
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Table 1. Median Fluorescent Intensity measuring viable HeLa cells positive for reactive
oxygen species (ROS) production. Value indicates median fluorescent intensity of each
sample (done in triplicate): non treated control without dye (NTC-), NTC with dye (NTC+),
69 µg/mL InP/ZnS and 167 µg/mL InP/ZnS. Two dyes used to measure two molecules of
ROS: peroxynitrite by DHR, and superoxide by DHE.

SAMPLE

DHR

DHE

NTC-

18895
4600
0

31636
50699
47372

NTC+

2258
2445
2736

24078
19419
24810

69 µg/mL

32128
28511
34287

38506
39040
36109

167 µg/mL

37152
39439
30392

36938
42238
49376
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Figure 1. STEM images of InP/ZnS (530nm) at low (left) and high (right) magnifications.
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Figure 2. EDAX spectra of InP/ZnS (530nm) QD to verify elemental
composition.
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Figure 3. Intensity size distribution of INPW530 obtained by Dynamic Light
Scattering
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Figure 4. UV-Vis absorption spectra of INPW530 (a) Full spectra; (b) Spectra for
wavelength range of 400 to 700nm.
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Figure 5. UV (365nm) light excitation of InP/ZnS QDs 530nm (green) on silicon
substrates (top) and in liquid (bottom).
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(B)

(A)

Figure 6. Effects of InP/ZnS QD on cell viability measured by XTT reagents. (A) HeLa
cells show minor reduction in cell viability shown through 28 µg/mL and significant reduction
at 167 µg/mL. Positive control with DMSO treatment shows statistically significant reduction
in viability at higher percentages of DMSO. (B) Fibroblast cells have no significant decrease at
all InP/ZnS concentration treatments (* = p < 0.05, **** = p < 0.0001.).
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Figure 7. ROS measurements with both DHE and DHR at varied InP/ZnS QD
concentrations: (A and B): Bar graphs comparing average percentages of ROS positive
cells when dyed with DHE and DHR, respectively. Non-treated controls shown without
(NTC-) and with (NTC+) dye. (C-E): Flow cytometer peaks taken from ROS Assay of
samples dyed with DHR. A second, larger peak represents ROS production. (C) dyed,
untreated control. (D) dyed sample treated with 69 µg/mL InP/ZnS. (E) sample treated with
167 µg/mL InP/ZnS. (F-H) Peaks of samples dyed with DHE. (F) dyed, untreated control.
(G) dyed sample treated with 69 µg/mL InP/ZnS. (H) dyed sample treated with 167 µg/mL
InP/ZnS. (* = p < 0.05, **** = p < 0.0001)
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Figure 8. Levels of early and late apoptosis after InP/ZnS treatment: (A and B): Bar
graph illustrating percent of apoptosis recorded by flow cytometer in samples treated with
varying concentrations of InP/ZnS. NTC- represents non-treated control without dye and
NTC+ is with dye. (C-E) Flow cytometer images of gated apoptosis levels. Each quadrant
represents a stage of apoptosis: -/- control, +/+ late apoptosis, and +/- early apoptosis. ©
represents dyed control group, (D) represents 69 µg/mL of InP/ZnS, and (E) represents 167
µg/mL of InP/ZnS. Error bars indicate standard deviation of samples. Statistically significant
results are indicated based on P-values: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p <
0.0001.
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Figure 9. Altered up and down regulated processes: Bar graph representing number of
genes upregulated (A) and downregulated (B), based on having p-value < 0.05. Genes
grouped by common processes.
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(A)

(B)

Figure 10, A and B: Visualization of altered processes in the presence of InP/ZnS.
Upregulated processes (A) observe evidence of metastatic inhibition, apoptosis due to autocrine
release, and cytokine release. Downregulated processes (B) show pathways involving
proliferation inhibition, increased ROS production, and varying levels of degradation. To the
left of each model is a chart depicting each gene involved, along with the corresponding Log2
Fold Change value and P-value found with transcriptome analysis.
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